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Abstract
In the processing of biopharmaceuticals, viral clearance and viral safety are important for
the development of monoclonal antibodies. Murine xenotropic leukemia virus (XMuLV) is one
of the retroviruses, recommended by Food and Drug Administration (FDA) as a model virus for
viral clearance via inactivation from therapeutics derived from Chinese hamster ovary cells
(CHO). A robust and effective method was investigated to clear or inactivate endogenous viruses
by low pH inactivation. The effects of different conductivity and inactivated time on XMuLV
clearance was determined. Acetate buffer was prepared with different conductivity, and 2%
XMuLV was spiked into acetate buffer. XMuLV virus particles could be effectively inactivated
in acetate buffer at pH 3.6. According to TICD50 assay, the inactivation time of around 60 minutes
was enough to clear all the viruses with more than 4 logs reduction value (LRV). Also, 50 mM
acetate buffer has the most rapid inactivation process. TICD50 assays were able to determine the
XMuLV virus titer within 95% confidence level, by using 8 replicates and 10-fold series dilution
factor.

1. Introduction
Biological and biochemical products have high risks of contamination from chemical
impurities, bacteria, fungi, and the most dangerous one is from viruses. Viral contamination will
affect raw materials, cell lines, cell culture process, and downstream processing (1). Thus, viral
clearance and viral safety were critical for products produced by mammalian cells such as
monoclonal antibodies (mAbs) because mammalian cells are highly sensitive to viral
contamination by adventitious viruses. For example, Chinese hamster ovary cells (CHO) should
express non-infectious retroviruses or retroviral-like particles during the production of
therapeutics (2-3). As applying a virus inactivation method during downstream production, it
could effectively eliminate concerns about underlying infectious, adventitious or dangerous
agents. Commonly, two dedicated, virus clearance steps, such as viral removal and viral
inactivation are included in the purification process. But virus inactivation processes are stable
processes and less sensitive to minor factors than the viral removal process. As a result, virus
inactivation is generally robust and effective (2,4).

One of the effective inactivation methods is low pH inactivation, performed by spiking
enveloped viruses such as XMuLV, pseudorabies Virus, and herpesviruses into the low pH
solution, which provides at least 4 logs of virus clearance for these viruses (7-8). For mAbs and
Fc fusion proteins production, acidified buffer always follows the inactivation, and these
enveloped viruses should be hold statically in for at least over 30 minutes to completely damage
the surface glycoproteins and prevent the viruses infecting the cells (8,9). At the end of
inactivation holding times, the acidified buffer with viruses is neutralized to pH 7 (9,10).

In the process of viral inactivation, XMuLV is used as inactivation model virus, produced
by Mus Dunni cells and mink lung cells (5). As XMuLV is similar to gamma retrovirus, a
nonmurine cell line PG-4 cell line is used to propagate the virus. PG-4 cells were astrocyte,
moloney murine sarcoma virus transformed, using for detection and quantitation of replication
competent retroviruses. PG-4 cells are resisted to infection and focus formation by ecotropic
murine leukemia virus (5-6).

2. Material and Methods
PG-4 cells, McCoy’s 5A medium, fetal bovine serum (FBA) were purchased from
American Type Culture Collection (ATCC, Manassas, VA). Penicillin/streptomycin solution
(10,000 U/mL) was purchased from ATCC (Manassas, VA), stored at - 20o C . Sterile
phosphate buffer saline without calcium and magnesium (PBS), and sodium acetate trihydrate
(CH3COONa+3H2O) were purchased from VWR Scientific (Radnor, PA). 0.25% trypsin- 0.53
mM EDTA solution(1X), trypan-blue (0.4%), and acetic acid (CH3CO2H) were purchased from
Millipore Sigma (Burlington, MA) and kept frozen at - 20o C . Sterile deionized water (DI
water) was collected through water Pro/RO reverse osmosis plus deionization purification
system by Labconco Corp (Kansas City, MO). L-Glutamine in220mM solution (292 mg/mLGlutamine in 0.85% NaCl) was purchased from VWR scientific (PA). Tris base (C4H11NO3) was
purchased from G-biosciences (St. Louis, MO).
All the experiments were safely run inside the laminar flow cabinet. Different size of the
serological pipettes and pipette tips as well as 15 and 50mL, sterile centrifuge tubes, micropipette
and sterile disposable pipette tips, 25 and 75 cm2 sterile cell culture flasks and 96-well flatbottom cell culture plate (sterile) were used in cell recovery, cell passaging and TCID50 assay. All
equipment was sprayed by 70% IPA before entering the hood.

2.1 PG-4 Cell Line Recovery and Passaging
2.1.1 PG-4 Cell Recovery
McCoy’s 5A medium, L-Glutamine (LG), FBS were warmed up at 37o C

in a cell

culture incubator with 5% CO2. Penicillin were thawed at room temperature without light under
aluminum foil. Afterwards, a total of 20 mL of cell medium was prepared by adding in 20 mL of
McCoy’s 5A medium with 1% LG, 2% FBS, and 0.01% penicillin was prepared in a 50 mL
sterile centrifuge tube. A total of 5 mL of prepared medium was transferred into a 25 cm2 cell
culture flask. A vial of frozen PG-4 cells was taken from the liquid nitrogen tank and thawed
with

o

37 C

water bath, agitating back and forth with no more than 3 minutes. The warmed

cell suspension was transferred into a 15 mL of medium drop by drop and mixed gently. After
that, it was centrifuged at 1500 RPM for 5 minutes. A clear wall of cells attached on the
centrifuge tube could be observed. The supernatant was removed from the other side of the wall
carefully. The rest of 5 mL medium was resuspended into the cell pallet and transferred into 25
cm2 flask. Finally, cells were kept in the cell culture incubator.

2.1.2 PG-4 Cell Passaging
A total of 30 mL of passaging medium was prepared in a 75 cm2 sterile cell culture flask
with the same contents as the cell recovery medium. Afterwards, the old cells were taken and
observed under the inverted light microscope to check if the cells reached 50-60% confluence.
Using a 10 mL serological pipette to aspire all the old medium from the 25 cm2 flask for the cells
to be passaged. 10 mL of sterile warm PBS was used to wash out the cell debris and remaining
old medium. After that, 2.5-3 mL trypsin-EDTA (TE) was added to cell monolayers to detach the

cells. After incubating with TE for 3-5 minutes, cells were observed under microscope to check if
all the cells are single and floating. Then, 5 mL of complete medium was aspirated into the cell
to disperse the cells. The cell suspension was then transferred into a 15 mL centrifuge tube and
centrifuged at 130 xg for 5 minutes. After removing the supernatant, cells were suspended in 5
mL of fresh complete medium. A designated number of cells were counted and transferred for
the next passage with 20mL of medium remained in the flask (passage ratio at 1:4 to 1:10).

3. XMuLV Virus Inactivation in Low-pH Acetate Buffer
3.1 Acetate Buffer Preparation
20, 50 and 100 mM acetate buffer solutions were prepared using 100 mL with DI water,
appropriate amount of sodium acetate and acetic acid, at low pH 3.6 (Table 1). After pH and
conductivity were measured, the acetate buffers were equilibrated in an incubator at 18 °C for 2
hours.
Table 1. Initial condition for preparing acetate buffers at different concentration
Buffer

Sodium Acetate

Acetate Acid

Concentration(mM)
20mM
50mM
100mM

(mg)
17.61
44.03
88.05

( μL )
107.08
267.07
535.41

3.2 Virus Propagation on PG-4 Cells and Virus Inactivation
After 2 hours of incubating, 100 mL acetate buffer was filtered with Millex-GP syringe
filter. The filtered buffer was transferred into 100mL baker. A 40 mL filtered buffer was divided
into tubes, containing 10 mL of buffer for each tube. These buffers were used to measure pH and
conductivity after filtering. They were also used to test the amount of 1 M tris needed in order to
increase the pH to 7. Then, this predetermined volume of 1M tris buffer was added into each of

the six tubes for neutralizing virus-buffer sample later (Table 2). The rest 60 mL of buffer was
spiked with 2% XMuLV virus. As the beginning of the kinetic study, 1.2 mL XMuLV virus was
spiked into 60 mL buffer and mixed well. After 1 minute, two of 10 mL inactivated virus-buffer
were transferred into the tubes, one for pH and conductivity control, one for determining the
virus titre with 1M tris to terminate the inactivation process. Then, after 5, 15, 30, 60 minutes,
each 10 mL of inactivated virus-buffer sample was pipetted into tubes contained with 1 M tris.
Thereafter, inactivated XMuLV stock was diluted by 10-fold series dilution factor for titer
determination using TCID50 assay. After seeding PG-4 cells for 24 hours, the cells were
inoculated with diluted XMuLV stock by 8 replicates in 96 well plates. The cocultivation would
last for 7 to 8 days. On day 7, the samples were ready for reading according to TCID50 assay.
Table 2. Initial pH and conductivity of acetate buffer for inactivation, and 1M tris added to
neutralize the pH and conductivity
Buffer
Concentration
(mM)
20
50
100

Initial
pH
3.60
3.61
3.60

Initial
Conductivity
( μS/cm )
256
773
1100

1M Tris
Neutralized
( μL )
185ul
490ul
970ul

Final
pH
7.00
7.01
7.00

Final
Conductivity
( μS/cm )
1141
2853
4450

3.3 TCID50 Assay to Determine Virus Titre
On day 1, 100 μl newly-made cell suspension was added to each well of 96-wells plate
and incubated at 37oC overnight. On day 2, after cells seeding were complete and reach the 20%
confluency, all inactivated virus samples were assayed for XMuLV infectivity by using TCID50
assay (3). Before TCID50 titration, all samples were diluted 10-fold series with fresh medium to
eliminate cytotoxic effects. PG-4 cells were infected by 100 μl of diluted samples on 96-well
plates, including the inactivated samples and original virus stock. Virus titre, and 95%

confidence level for the log titre of the virus stock were determined by method of Spearmankärber (4).

4. Results and Discussion
After 7-8 days, the plates were ready for evaluation; by distinguishing health PG-4 cells
(Fig. 1a) or infected PG-4cells (Fig. 1b), the wells would be recorded as negative or positive.
Also, PG-4 cells were infected by inactivated XMuLV viruses at 1, 5, 15, 30 and 60 minutes (Fig
1c-1g). For inactivation time below 15 minutes, there were plenty of regions under infection by
XMuLV. However, as the inactivation time increased, the infected region got smaller. Until 60
minutes, it was no infected PG-4 cells exiting. Based on figure 1, inactivation time around 60
minutes is enough to clear XMuLV virus, and TCID50 assay was not able to detect infection over
60 minutes.

Figure 1 Infected PG-4 cells on day 7. A) Negative control- health PG-4 cells. B) Positive
Control- infected by XMuLV virus. C)-D) infected PG-4 cells by inactivated XMuLV virus at
different time.

The pH and conductivity of control samples after being inactivated were measured to
make sure the pH was still around the same range as the buffer, and pH slightly increased around
3.68 or 3.7 (Table 3). Also, virus tire and LRV were calculated with different inactivation kinetics
and shown in Table 4.
Table 3. pH and conductivity ( μS/cm

)

measured after virus was spiked into 20, 50, and

100 mM acetate buffer

Standard deviation and 95% confidence level indicated the accuracy and repeatable of
TCID50 assay. Table 4 was shown sample with 20 mM acetate buffer, the average original virus
stock titre was 5.92 logs/mL, during each inactivation time, the titre was decreased till
1.58logs/mL. Until 60mins, TCID50 assay was not able to determine the infection of XMuLV
virus. Also, the pooled standard deviation for all samples were less than 0.5 logs and resulted in
95% confidence level less than 0.5 logs, and the variation within the assay didn’t exceed ± 0.5
logs. Also, samples with 50mM and 100mM acetate buffer, and the original virus stock titre for
both was calculated as 6.00 logs/mL, and for each inactivation kinetics, the average titre was
decreased. Still, for 50mM kinetics, the pooled standard deviation for all samples was less than
0.5 logs and resulted in 95% confidence level less than 0.5 logs, and the variation within the
assay didn’t exceed ± 0.5 logs. Thus, initial precision experiments are proved that those assays
were able to determine the XMuLV virus titre within 95% confidence level, by using 8 replicates
and 10-fold series dilution factor. However, for 100mM kinetics, the inactivation time at 5

minutes, the standard deviation of 0.26 resulted in a 95% confidence level of 0.52 logs, and the
variation within the assay exceeded ± 0.5 logs, thus, for more accurate determination, this
kinetics with inactivation time at 5 minutes, should be repeated.
Table 4. Log total virus in 10mL, Log reduced value (LRV), 95% confidence level for
20mM, 50mM, and 100mM Acetate buffer.

Time
(Mins)
0
1
5
15
30
60

20mM
Total Virus
LRV
(logs)
6.92±0.64
4.42±0.5
3.92±0.3
3.33±0.42
2.83±0.28
2.58±0.08

0.00
2.50
3.00
3.58
4.08
4.33

50mM
Total Virus
LRV
(logs)
7.00±0.78
3.69±0.18
3.08±0.30
2.92±0.30
2.83±0.24
2.50±0.00

0.00
3.33
3.92
4.08
4.17
4.50

100mM
Total Virus
LRV
(logs)
7.08±0.72
4.25±0.50
3.17±0.52
3.08±0.30
2.67±0.18
2.58±0.08

0.00
2.83
3.17
4.00
4.41
4.50

Log reduced value was used to determine the number of viruses eliminated from the
inactivation kinetics. LRV was calculated by the equation

LRV =log 10 ((C F∗V f )/(C∗V ))

(11). Cf and Vf refer as original virus titre and original virus volume, in here is 10mL. C and V
refers as filtrate virus titre and filtrated virus volume, still 10mL. After calculation, LRVs was
determined by plotting the each LRV kinetics curve with inactivation time. With long
inactivation time, the curve was increased sharply and stay flat. At the beginning of 1-minute
inactivation, 50mM inactivation kinetics had the most rapid increase on LRV, and for 20mM
kinetics, it had smallest increase on LRVs (Fig. 2a) In addition, 50mM buffer has the most
decreased on total amount of virus in 2.5 logs/10mL sample volume, and 20mM, 100mM has the
same decreased value, reaching 2.58 logs/10mL (Fig. 2b). Accordingly, for all of kinetics, around
60-minutes inactivation, there were no more XMuLV virus being detected, and LRVs reached
4.50, which showed that most of XMuLV viruses were inactivated by the acetate buffer at pH 3.6

with different conductivity. Thus, the final LRVs were greater than 4.0-4.5. Also, the inactivated
kinetics were independent on the changing conductivity.
LRV VS. XMuLV inactivated in different time

log Reduced Value

5
4
3

LRV-20mM
LRV-50mM
LRV-100mM

2
1

B

log of total virus in 10mL acetate buffer
Total Virus (log/mL)

A

8
7
6
5
4
3
2
1
0
0 Min 1 Mins 5 Mins 15 Mins 30 Mins 60 Mins

0
0 10 20 30 40 50 60
Virus Inactivation Time (Min)

Virus Inactivation Time (Min)
20mM

50mM

100mM

Figure 2 A) Trends for log reduced value with XMuLV virus being inactivated in different time.
B) Error bar for log total virus in 10mL inactivation buffer with different time

5. Conclusion
The purpose of this project was to investigate the virus clearance method with low pH
and determine if conductivity and inactivation duration had any effective impact on virus
clearance. The entire work was performed by PG-4 cell line passaging and TCID50 assay to
determine the virus titre and LRV (log reduced value). At pH 3.6, all of the kinetics had
completed the inactivation process around 60-minutes. Also, standard deviation resulted in 95%
confidence level within 0.5 logs, which proved that this inactivation kinetic was effective and
accurate. There were no more XMuLV being detected by TCID50 assay until 60 minutes. For 60
minutes inactivation, it was enough to obtain > 4 logs LRVs.
In summary, XMuLV virus particles could be effectively inactivated in acetate buffer
with different conductivity at pH 3.6. Also, inactivation efficiency was independent on changing
conductivity and dependent on holding duration. However, based on data, 50mM acetate buffer

had the best inactivation on XMuLV virus particles. Furthermore, the kinetics over 60 minutes
should be tested with other assays to check whether all the viruses got cleared.
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